KR20180081327A - Composition for skin conditioning comprising Adenophora Stricta extract - Google Patents
Composition for skin conditioning comprising Adenophora Stricta extract Download PDFInfo
- Publication number
- KR20180081327A KR20180081327A KR1020170002437A KR20170002437A KR20180081327A KR 20180081327 A KR20180081327 A KR 20180081327A KR 1020170002437 A KR1020170002437 A KR 1020170002437A KR 20170002437 A KR20170002437 A KR 20170002437A KR 20180081327 A KR20180081327 A KR 20180081327A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- skin
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 241001633574 Adenophora stricta Species 0.000 title abstract description 5
- 230000003750 conditioning effect Effects 0.000 title 1
- 239000000428 dust Substances 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 19
- 235000008434 ginseng Nutrition 0.000 claims description 19
- 230000037380 skin damage Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 9
- 108091027981 Response element Proteins 0.000 claims description 4
- 239000002676 xenobiotic agent Substances 0.000 claims description 4
- 230000002034 xenobiotic effect Effects 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 3
- 210000003491 skin Anatomy 0.000 description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 240000004371 Panax ginseng Species 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 235000020710 ginseng extract Nutrition 0.000 description 16
- -1 skin Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000006071 cream Substances 0.000 description 13
- 238000007796 conventional method Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 239000000230 xanthan gum Substances 0.000 description 10
- 229920001285 xanthan gum Polymers 0.000 description 10
- 235000010493 xanthan gum Nutrition 0.000 description 10
- 229940082509 xanthan gum Drugs 0.000 description 10
- 229920002498 Beta-glucan Polymers 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000000254 damaging effect Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 5
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 240000006439 Aspergillus oryzae Species 0.000 description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 241001506766 Xanthium Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010074109 interleukin-22 Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004071 soot Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001633583 Adenophora Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 241000589652 Xanthomonas oryzae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 230000003695 hair diameter Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
Description
피부외용제 조성물에 관한 것으로서, 보다 구체적으로 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어에 우수한 효과를 가지는 피부외용제 조성물에 관한 것이다. 또한, 본 발명은 사삼 추출물을 포함하는 화장료 조성물 및 의약외품 조성물에 관한 것이다.The present invention relates to a composition for external application for skin and, more particularly, to a composition for external application for skin, which has an excellent effect on protection of skin damage caused by fine dusts containing extracts of ginseng as an active ingredient. The present invention also relates to a cosmetic composition and a quasi-drug composition comprising ginseng extract.
최근 산업발달 및 생활패턴의 변화로 인한 외인성 피부질환이 크게 증가하고 있다. 특히 최근 생활환경이 변화함에 따라 자동차, 공장으로부터 내뿜어지는 매연이 많아지고 있다. 매연은 가스형태뿐 아니라 미세먼지(PM10), 초미세먼지(PM2.5) 등 분진형태로도 도시에 존재한다. DPM(Diesel Particulate Matter)은 호흡기뿐 아니라, 피부에도 안 좋은 영향을 미치게 된다. 구체적으로, 미세먼지로 인하여 피부세포에서의 사이토카인의 과발현을 통해 염증이 일어나 홍반, 아토피, 건선, 여드름 등 염증성 질환이 심화되기도 하고, 경피의 수분 손실이 심해져 피부장벽이 손상이 되고, 손상된 피부장벽을 통해 DPM가 더욱 많이 침투가 가능해 지게 된다. 깊숙이 침투된 DPM은 진피층에서의 콜라겐손실을 가져와 피부 탄력 저하를 야기하기도 한다. 특히나 TCDD같은 다이옥신류는 염소성 피부염등의 질병을 야기하기도 한다. Recently, extrinsic skin diseases due to changes in industrial development and life patterns have been greatly increased. Especially, as the living environment has changed recently, soot emitted from automobiles and factories is increasing. Soot exists not only in the form of gas but also in dust form such as fine dust (PM10) and ultrafine dust (PM2.5). DPM (Diesel Particulate Matter) has an adverse effect on the skin as well as the respiratory tract. More specifically, inflammation occurs due to overexpression of cytokines in skin cells due to fine dusts, and inflammatory diseases such as erythema, atopy, psoriasis, and acne are deepened, and skin barrier is damaged due to increased transdermal water loss, The barrier will allow more penetration of the DPM. Deeply penetrated DPM can cause collagen loss in the dermis, resulting in reduced skin elasticity. In particular, dioxins such as TCDD may cause diseases such as chlorotic dermatitis.
피부에는 미세먼지 등 외부의 생체이물이 침투하면 이를 방어하기 위한 대사 메커니즘이 있다. 구체적으로, 피부각질세포의 AHR(Aryl Hydrocarbon Receptor)이라는 수용체를 통해 XRE(Xenobiotic Response Element)라는 생체이물대사인자를 활성화시켜 이런 생체이물들로부터 피부를 방어하기 위한 방어인자들을 조절한다. 그러나, 요즘처럼 대기의 오염수준이 심각한 상황에서는 대기오염물질에 대항해 피부를 방어하는 과정에서 오히려 XRE가 과도하게 활성화되어 염증반응, 수분손실 등의 상기에서 언급한 피부 질환이 나타날 수 있다. There is a metabolic mechanism in the skin to defend it when water enters the living body such as fine dust. Specifically, it activates a bioinduced signer called XRE (Xenobiotic Response Element) through a receptor called Aryl Hydrocarbon Receptor (AHR) of keratinocytes to regulate defensive factors for defending skin from these living organisms. However, in recent years, when the air pollution level is seriously high, XRE is excessively activated in protecting the skin against air pollutants, resulting in the above-mentioned skin diseases such as inflammation reaction and water loss.
이에 적절한 XRE의 활성 조절을 통해서 염증반응, 수분손실 등 피부질환을 조절할 수 있는 방법의 개발이 시급한 상황이다. Therefore, it is urgently necessary to develop a method for controlling skin diseases such as inflammation reaction and water loss by controlling the activity of XRE.
이러한 배경하에, 본 발명자들은 미세먼지에 의한 피부 손상 방어 효과가 우수한 물질에 관하여 연구를 수행하였으며, 이에 사삼 추출물을 유효성분으로 포함하는 피부외용제 조성물이 과발현된 XRE의 활성 억제, 보습 등에 효과를 나타냄을 규명하여, 이를 활용한 피부외용제 조성물, 화장료 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Under these circumstances, the inventors of the present invention conducted studies on a substance having excellent skin damaging effect due to fine dust, and thus showed an effect on the inhibition of XRE activity and moisturizing of XRE overexpressed composition containing external extract of Xanthan gum extract as an active ingredient And has completed the composition for skin external application, the composition for cosmetics and the composition for quasi-drugs using the same.
본 발명의 하나의 목적은 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 피부외용제 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for external application for skin for protecting against skin damage due to fine dust comprising extract of ginseng as an active ingredient.
본 발명의 다른 목적은 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for preventing skin damage caused by fine dust comprising extract of ginseng as an active ingredient.
본 발명의 또 다른 목적은 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 의약외품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a quasi-drug composition for protecting against skin damage caused by fine dust comprising extract of ginseng as an active ingredient.
상기 목적을 달성하기 위한, 본 발명의 하나의 양태는 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 피부외용제 조성물을 제공한다.In order to accomplish the above object, one aspect of the present invention provides a composition for external application for skin for protecting against skin damage caused by fine dust comprising extract of ginseng as an active ingredient.
본 발명에서 사용되는 용어 "사삼(Adenophora Stricta)"은 잔대 또는 당잔대의 뿌리를 의미한다. 한약재로 쓰이며, 진액을 보충하여 폐를 윤택하게 하고 열을 식히며 담을 없애 인후건조, 마른기침, 가래, 해수, 천식 등에 쓰인다. 또한, 위음 부족으로 입안이 마르고 인후가 건조하며 대변이 굳는 변비 증상 등에 사용한다. 사삼은 다른 이름으로 아데노포라, 트리가네닌진, 당잔대, 남사삼, 지모, 양파내, 사엽사삼, 백사삼, 토인삼, 북사삼, 조선삼, 털모싯대, 당모싯대, 둥근잎잔대, 살구잔대 등으로 불리워진다. As used herein, the term " Adenophora Stricta "refers to the roots of the remainder or the sacrum. It is used as medicinal herb. It replenishes the essence to soften the lungs, to cool the fever, to get rid of the feces, to dry the throat, dry cough, sputum, seawater and asthma. In addition, the lack of lethargy, dry mouth, dry throat, constipation symptoms, such as constipation is used. Sansam is also known as Adenophora, Triganeininjin, Tangzan, Namsa, Zumo, Onion, Sasaepsam, Bassam, Ginseng, Balsam, Chosam, And so on.
본 발명에서의, "추출물(extract)"은, 목적하는 물질을 다양한 용매에 침지한 다음, 상온, 저온 또는 가온 상태에서 일정시간 동안 추출하여 수득한 액상성분, 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미한다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다."Extract" in the present invention means a liquid component obtained by immersing a desired substance in various solvents and then extracting it at a room temperature, a low temperature, or a warmed state for a predetermined time, a liquid component obtained by removing the solvent from the liquid component Means a product such as a solid. In addition, in addition to the above-mentioned results, the present invention can be broadly interpreted to include all of the diluted solution, the concentrated solution thereof, the adjusted product thereof, and the purified product.
본 발명에 있어서, 상기 추출물은 사삼 추출물을 의미한다. 상기 사삼 추출물은 천연, 잡종, 변종식물의 다양한 기관으로부터 추출될 수 있고, 예를 들어 뿌리, 지상부, 줄기, 잎, 꽃, 열매의 몸통, 열매의 껍질뿐만 아니라 식물 조직으로부터 추출 가능하다. 상기 사삼 추출물은 물 또는 다양한 유기용매 등으로 추출하여 수득할 수 있다. 이때, 사용되는 유기용매는 추출물을 수득할 수 있는 한, 특별히 이에 제한되지 않으나, 구체적으로는 물, 극성용매 또는 비극성용매가 될 수 있고, 보다 구체적으로는 물, 탄소수 1 내지 6의 저급 알코올(메탄올, 에탄올, 프로판올 또는 부탄올 등), 이들의 혼합용매 일 수 있으며, 가장 구체적으로는 메탄올 또는 이의 혼합용매일 수 있으나 이에 제한되지 않는다.In the present invention, the extract means a ginseng extract. The ginseng extract can be extracted from various organs of natural, hybrid, and variant plants and extracted from plant tissues as well as roots, stem parts, stems, leaves, flowers, fruit bodies, fruit husks. The ginseng extract can be obtained by extraction with water or various organic solvents. The organic solvent to be used may be water, a polar solvent or a nonpolar solvent, and more specifically, water, a lower alcohol having 1 to 6 carbon atoms (for example, Methanol, ethanol, propanol or butanol), or a mixed solvent thereof, most specifically, methanol or a mixture thereof, but is not limited thereto.
또한, 상기 추출물을 수득하기 위한 방법은 사삼 추출물을 수득할 수 있는 한, 특별히 이에 제한되지 않으나, 구체적으로는 상기 사삼의 뿌리, 줄기, 잎, 열매, 꽃, 이들의 건조물, 가공물 등을 상기 용매에 침지하고, 상온에서 추출하는 냉침추출법, 가열추출법, 초음파를 가하여 추출하는 초음파추출법, 환류냉각기를 이용한 환류추출법 등의 방법을 사용할 수 있다.In addition, the method for obtaining the above extract is not particularly limited as long as it can obtain a ginseng extract. Specifically, the ginseng root, stem, leaf, fruit, flower, dried product, A heating extraction method, an ultrasonic extraction method in which ultrasonic waves are applied to the extraction, and a reflux extraction method using a reflux condenser.
본 발명에 따른 "외용제"는 외용으로 제공되는 제제이고, 피부 외용제 조성물은 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유하여 제형화될 수 있다. 이는 국소적용에 적합한 모든 제형으로서, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이, 팩 또는 콘실 스틱의 형태로 제공될 수 있다. 포말(foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있으나, 이에 제한되는 것은 아니다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The "external preparation" according to the present invention is a preparation provided for external use, and the composition for external application for skin may be formulated containing a cosmetically or dermatologically acceptable medium or base. It may be any formulation suitable for topical application, for example, as a solution, a gel, a solid, a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, Or in the form of a cream, skin, lotion, powder, ointment, spray, pack or conical stick. But is not limited to, in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions may be prepared according to conventional methods in the art.
본 발명에서 상기 피부외용제 조성물은 미세먼지에 의한 피부 손상 방어 효과를 가질 수 있으나, 이에 제한되지 않는다. In the present invention, the composition for external application for skin may have a skin damaging effect due to fine dust, but is not limited thereto.
본 발명에서의 "미세먼지(Diesel Particulate Matter)"라 함은 피부에 침투하여 염증반응을 일으키고 피부장벽에 손상을 주어 콜라겐 합성을 저해하여 피부의 노화를 일으키는 미세한 먼지를 의미한다. 미세먼지는 직경에 따라 PM-10과 PM-2.5 등으로 구분할 수 있다. 구체적으로 직경 PM-10의 미세먼지는 1,000분의 10mm보다 작은 먼지를 의미하고, 직경 PM-2.5의 미세먼지는 1,000분의 2.5mm보다 작은 먼지로, 머리카락 직경(약 60㎛)의 1/20 내지 1/30 크기보다 작은 입자이다. 미세먼지는 천식과 같은 호흡기계 질병을 악화시키고, 폐 기능의 저하를 초래한다고 알려져 있으나, 근래에는 미세먼지와 피부 이상 반응의 관계에 대한 보고가 증가하고 있다. 미세먼지는 다른 이름으로 DPM 등으로 불리워지고 있다, 또한, 본 발명에서는 상기 미세먼지는 DPM과 혼용될 수 있다. The term "Diesel Particulate Matter" in the present invention means fine dust that causes skin aging by inhibiting collagen synthesis by infiltrating the skin to cause an inflammatory reaction and damaging the skin barrier. Fine dust can be classified into PM-10 and PM-2.5 depending on the diameter. Specifically, the fine dust of the diameter PM-10 means dust less than 10 mm of 1,000, and the fine dust of the diameter PM-2.5 is dust less than 2.5 mm of 1,000 and the diameter of 1/20 of the hair diameter (about 60 μm) To less than 1/30 size. Fine dusts are known to aggravate respiratory diseases such as asthma and cause lung function deterioration. Recently, however, there has been an increasing report on the relationship between micro dust and skin adverse reactions. The fine dust is sometimes referred to as DPM or the like. In the present invention, the fine dust may be mixed with the DPM.
본 발명에서의 "미세먼지에 의한 피부 손상 방어"는 상기에서 설명한 미세먼지가 피부속으로 침투하여 손상을 일으키는 것을 방어하는 것을 의미한다. 구체적으로 미세먼지 등이 피부에 침투하는 경우 이를 방어하기 위한 메커니즘이 작동하며, 특히 피부 각질세포의 AHR(Aryl Hydrocarbon Receptor)이라는 수용체를 통해 XRE(Xenobiotic Response Element)라는 생체이물대사인자를 활성화시켜 이런 생체이물들로부터 피부를 방어하기 위한 방어인자들을 조절하는 것일 수 있다. 또한, 본 발명의 미세먼지에 의한 피부 손상 방어는 미세먼지에 의한 피부 자극 방어/완화, 미세먼지로부터 피부 염증 방어, 미세먼지로부터 피부 손상 억제/개선, 미세먼지에 의한 피부/피부 세포/피부 장벽 손상 방지, 미세먼지 환경에서의 피부 항상성 유지 등을 의미하는 것일 수 있으나, 이에 제한 되지 않는다.In the present invention, the term "skin damage protection by fine dust" means that the above-mentioned fine dust penetrates into the skin to prevent damage. Specifically, a mechanism for defending against penetration of fine dusts into the skin works, and in particular, activation of a xenobiotic response element (XRE) called XRE (Xenobiotic Response Element) through a receptor called AHR (Aryl Hydrocarbon Receptor) It may be to adjust the defense factors to defend the skin from the water. In addition, the skin damage protection by the fine dust of the present invention can be used to prevent / mitigate skin irritation due to fine dust, to protect skin inflammation from fine dust, to inhibit / improve skin damage from fine dust, to skin / skin cells / skin barrier Prevention of damage, maintenance of skin homeostasis in a fine dust environment, etc. However, the present invention is not limited thereto.
미세먼지가 많은 상황에서는 피부 방어하는 과정에서 오히려 XRE가 과도하게 활성화되어 염증반응, 수분손실 등을 일으키는 원인이 된다. 본 발명에서의 미세먼지에 의해 과발현된 XRE의 활성 감소는 이를 감소시켜 정상수준으로 도달하게 하므로써 염증반응, 수분손실 등 피부질환을 조절하는 것을 말한다. In the case of fine dust, XRE is excessively activated in the process of defending the skin, causing inflammation reaction, moisture loss and the like. The decrease in the activity of XRE overexpressed by the fine dust in the present invention means that the skin condition such as inflammation reaction and water loss is controlled by decreasing the activity of XRE and thereby reaching a normal level.
구체적으로 AHR에 의한 XRE의 발현은 T세포 면역을 주도하고, 피부세포에서 사이토크롬 패밀리 (CYP1A1, CYP1B1), 인터루킨 패밀리 (인터루킨 1 베타, 인터루킨 6, 인터루킨 17, 인터루킨 22)등의 생체 방어물질 합성을 촉진하여 피부에서 면역반응을 촉진한다. 하지만 한 예로, TH17의 과도한 활성과 IL-17, IL-22의 합성이 이루어지게 되고 이러한 염증반응이 지속되면 건선, 자가면역의 병증이 나타나거나 심화될 수 있다. 유해한 환경 속에서 위와 같은 염증인자들의 발현이 지속이 되면 자가면역질환, 만성적인 피부질환을 야기하게 되고 특히나 미세먼지, 공해에 의한 피부 질환은 피부결의 문제에서 더 나아가 질병으로의 발전을 야기한다. 이러한 개개의 피부 질환에 대처하는 것은 한계가 있기 때문에 미세먼지에 의해 과도하게 유발된 XRE의 활성을 조절함으로써, 미세먼지에 대한 근본적인 피부 방어를 꾀할 수 있다.Specifically, the expression of XRE by AHR leads to T cell immunity, and the synthesis of bioactive defense substances such as cytochrome family (CYP1A1, CYP1B1), interleukin family (
구체적인 일 실시예에 따르면, 본 발명의 사삼 추출물을 사람의 정상 각질형성세포의 배양액에 첨가하여 생체이물인자(XRE)의 활성여부를 확인하였다. 구체적으로, DPM을 각질형성세포에 처리하여 XRE를 인위적으로 과발현 시킨 후, 사삼 추출물을 처리한 결과, DPM에 의해 과활성화된 XRE의 활성이 사삼 추출물에 의하여 정상수준으로 회복됨을 확인하였다(도 1). According to one specific embodiment, the ginseng extract of the present invention is added to the culture medium of human normal keratinocytes to confirm the activity of the bio-water factor (XRE). Specifically, DPM was treated with keratinocytes to artificially overexpress XRE and then treated with the extract of Xanthana ginseng. As a result, it was confirmed that the activity of XRE hyperactivated by DPM was restored to normal level by the extract of Xanthan gum (Fig. 1 ).
이를 통해, 사삼 추출물이 미세먼지에 의한 DPM에 의한 XRE의 과활성을 조절하여 피부자극을 방어해 줄 수 있음을 알 수 있다.Thus, it can be seen that the extract of Xanthium ginseng can protect the skin irritation by controlling the hyperactivity of XRE by DPM caused by fine dust.
본 발명의 사삼 추출물은 조성물의 총 중량에 대하여 0.0001 내지 5 중량%(w/w), 구체적으로는, 0.001 내지 3 중량%(w/w), 보다 구체적으로는 0.001 내지 0.5 중량%(w/w)으로 포함한다. 그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 피부외용제 및 화장료 조성물의 제형 및 성분, 피부 안전성, 용이성 등의 요건에 따라 조절될 수 있다.The ginseng extract of the present invention is used in an amount of 0.0001 to 5 wt% (w / w), specifically 0.001 to 3 wt% (w / w), more specifically 0.001 to 0.5 wt% (w / w). However, the composition of the present invention is not limited thereto, and can be controlled according to requirements of formulation and ingredients of skin external preparation and cosmetic composition, skin safety, ease of use, and the like.
상기의 목적을 달성하기 위한 다른 양태로서, 본 발명은 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 화장료 조성물을 제공한다.In accordance with another aspect of the present invention, there is provided a cosmetic composition for preventing skin damage caused by fine dust comprising extract of ginseng as an active ingredient.
상기 용어 사삼 추출물, 미세먼지에 의한 피부 손상 방어는 상기에서 설명한 바와 같다. The skin damaging protection by the above-mentioned quartz extract, fine dust is as described above.
또한, 본 발명의 화장료 조성물 또는 피부외용제는 상기 유효성분 이외에 통상적으로 허용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다. In addition, the cosmetic composition or external preparation for skin of the present invention may contain ingredients generally accepted in addition to the above-mentioned effective ingredients, and may contain conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and perfumes, .
본 발명의 화장료 조성물 또는 피부외용제는 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 제한되는 것은 아니다. 보다 상세하게는, 유연 화장수(스킨), 영양 화장수(밀크로션), 영양크림, 마사지크림, 에센스, 아이크림, 클렌징크림, 클렌징폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition or the external preparation for skin of the present invention may be prepared in any formulations conventionally produced in the art, and examples thereof include solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, -Containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray, but are not limited thereto. More specifically, it can be manufactured in the form of a flexible lotion (skin), a nutritional lotion (milk lotion), a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder .
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성 오일, 식물성 오일, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있으며, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시테이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 오일, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interface-active agent-containing cleansing, the carrier component is selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 발명은 사삼 추출물을 유효성분으로 포함하는 미세먼지에 의한 피부 손상 방어용 의약외품 조성물을 제공한다.According to another aspect of the present invention to achieve the above object, the present invention provides a quasi-drug composition for protecting against skin damage caused by fine dust comprising extract of ginseng as an active ingredient.
상기 용어 사삼 추출물, 미세먼지에 의한 피부 손상 방어는 상기에서 설명한 바와 같다. The skin damaging protection by the above-mentioned quartz extract, fine dust is as described above.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, .
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils such as sodium carboxymethylcellulose, , Injectable ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.
또한, 본 발명의 사삼 추출물을 유효성분으로 포함하는 조성물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 미세먼지에 의한 피부 손상 방어을 포함할 수 있을 것이다. 추가적인 미세먼지에 의한 피부 손상 방어을 포함하게 되면 본 발명의 조성물의 미세먼지에 의한 피부 손상 방어 효과는 더욱 증가될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 미백 성분으로서, 코즈산(Kojic acid), 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid); 당업계에 공지된 피부 탄력, 주름 개선 또는 보습 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 5 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 용이성 등의 요건에 따라 조절될 수 있을 것이다.In addition, when the composition comprising the extract of Xanthomonas gum extract of the present invention as an active ingredient is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may include skin damage protection by known fine dusts. The skin damage protection effect by the fine dust of the composition of the present invention can be further increased if the skin damage protection by the additional fine dust is included. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. The quasi-drug composition may be a whitening ingredient known in the art, such as a substance inhibiting tyrosinase enzyme activity such as kojic acid, arbutin, hydroquinone, L-ascorbic acid; Retinoic acid, TGF, proteins from animal placenta, betulinic acid and chlorella extract, as skin elasticity, wrinkle or moisturizing ingredients known in the art; And derivatives thereof, and various plant extracts. ≪ Desc /
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention can be exemplified by a disinfectant cleaner, a shower foam, a softener solution, a wet tissue, a coating agent, and the like. The formulation method, dosage, usage method, And the like.
또한, 본 발명의 상기 사삼 추출물을 유효성분으로 포함하는 의약외품 조성물은 개체의 피부에 도포하는 단계를 포함하는, 미세먼지에 의한 피부 손상 방어용, 피부 탄력 증진 또는 주름 개선용, 또는 피부 보습 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.In addition, the quasi-drug composition comprising the extract of Xanthomonas campestris as an active ingredient of the present invention can be used for skin damaging defense against fine dust, skin elasticity enhancement or wrinkle improvement, or skin moisturizing method . The subject includes, without limitation, mammals including rats, livestock, humans, and the like.
본 발명의 사삼 추출물을 유효성분으로 포함하는 피부외용제 조성물은 미세먼지에 의한 피부 손상 방어 효과가 우수하다. 구체적으로 본 발명의 사삼 추출물을 포함하는 조성물은 XRE 활성 감소 효과가 우수하므로 미세먼지에 의한 피부 손상 방어용 피부외용제 조성물로서의 활용도가 높다. 또한, 본 발명의 사삼 추출물을 유효성분으로 포함하는 조성물은 화장료 조성물 및 의약외품 조성물로서 사용할 수 있다.The composition for external application for skin comprising the extract of the present invention as an active ingredient is excellent in skin damaging effect by fine dust. Specifically, the composition containing the extract of Xanthomonas gentianus according to the present invention has a high effect of reducing XRE activity, so that it is highly utilized as a composition for external skin application for skin damage protection by fine dust. In addition, the composition comprising the ginseng extract of the present invention as an active ingredient can be used as a cosmetic composition and a quasi-drug composition.
도 1은 사삼 추출물의 XRE 활성 저해를 나타낸 것이다. Fig. 1 shows the inhibition of XRE activity by the extract of ginseng saponin.
이하 본 발명을 하기 예에 의해 상세히 설명한다. 다만, 하기 예는 본 발명을 예시하기 위한 것일 뿐, 하기 예에 의해 본 발명의 범위가 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the following examples.
실시예Example 1. One. 사삼Sasayam 추출물의 제조 Preparation of extract
사삼을 잘 세절한 후, 건조중량 100g을 플라스크에 넣고 추출용매(증류수) 1000g으로 25℃, 5시간 냉침 추출하였다. 냉침 추출된 추출물을 0.2μm의 기공 크기를 가진 필터로 여과하여 각각의 추출물을 제조하였다.After thoroughly finely dividing the ginseng, 100 g of the dry weight was placed in a flask, and the mixture was ice-extracted with 1000 g of an extraction solvent (distilled water) at 25 ° C for 5 hours. The cold extract extracts were filtered with a filter having a pore size of 0.2 μm to prepare respective extracts.
실험예Experimental Example 1. 세포 독성 평가 1. Assessment of cytotoxicity
실시예 1에서 제조된 사삼 추출물을 사람의 정상 각질형성세포(keratinocyte)의 배양액에 첨가하여 세포 수준에서의 세포 독성평가를 실시하였다. Cellular toxicity was evaluated at the cellular level by adding the ginseng extract prepared in Example 1 to the culture medium of human normal keratinocyte.
구체적으로, 사삼 추출물을 농도별로 처리한 후, 분광광도계를 이용하여 세포 생존능을 확인하였다. 인간 각질형성세포를 24웰 플레이트에 1X105 cell씩 넣고 부착 시킨 후, 24시간 배양하여 90% 이상 차게 되었을 때 사삼 추출물을 10㎍/㎖, 20㎍/㎖농도로 각각 처리하였다. 24시간 배양 후에 배지를 제거하고 각 well당 200 ㎕ 배지와 CCK8 용액 20㎕를 넣고 20분 동안 37℃, 5% CO2 배양기에서 배양한 후 450 nm에서 흡광도를 측정하였다. 처리하지 않은 well의 흡광도를 기준으로 하여 사삼 추출물이 세포 생존에 미치는 영향을 평가하였으며, 그 결과를 하기 표 1에 나타내었다. 모든 결과값은 3회 이상의 독립적인 실험을 거쳐 평균±표준편차(SD)로 나타내었다.Specifically, the extract was treated at different concentrations and then the cell viability was confirmed using a spectrophotometer. Human keratinocytes in a 24-well plate 1X10 5 Cells were added and adhered. After 24 hours of incubation, the extracts were treated with 10 ㎍ / ㎖ and 20 ㎍ / ㎖ respectively. After culturing for 24 hours, the culture medium was removed, and 200 μl of the medium and 20 μl of the CCK8 solution were added to each well. After incubation for 20 minutes at 37 ° C. in a 5% CO 2 incubator, the absorbance was measured at 450 nm. Based on the absorbance of the untreated wells, the effect of the extract on the cell viability was evaluated. The results are shown in Table 1 below. All results were expressed as mean ± standard deviation (SD) after three or more independent experiments.
그 결과, 표 1에 나타난 바와 같이, 사삼 추출물은 각각의 실험 농도에서 세포 독성을 일으키지 않는 것을 확인하였다. 이를 통해, 사삼 추출물이 피부 자극 유발 가능성이 낮고 안전한 물질임을 알 수 있다.As a result, as shown in Table 1, it was confirmed that the ginseng extract did not cause cytotoxicity at the respective experimental concentrations. As a result, it can be seen that the extract of Samamgwang is low in the possibility of skin irritation and is safe.
실험예Experimental Example 2. 2. 생체이물대사조절Biohydrogen metabolism regulation 확인 Confirm
실시예 1에서 제조된 사삼 추출물을 사람의 정상 각질형성세포(keratinocyte)의 배양액에 첨가하여 과도하게 활성화된 생체이물인자(XRE)를 조절하는 실험을 수행하였다. Experiments were conducted in which the ginseng extract prepared in Example 1 was added to the culture medium of human normal keratinocyte to regulate excessively activated bio-water factor (XRE).
구체적으로, 인간 각질형성세포를 48-웰 플레이트에 5X104 cell씩 넣고 부착 시킨 후, 24시간 배양하여 90% 이상 차게 되었을 때 K2® Transfection Reagent(Biontex)를 이용하여 인간 각질형성세포에서 XRE promoter를 일시적으로 과발현 시켰다. 그 후, 미세먼지(DPM)를 100㎍/㎖의 농도로 상기 세포에 처리를 하여 DPM에 의한 XRE promoter의 과활성화 여부를 확인하였다. Specifically, human keratinocytes were plated in a 48-well plate at a rate of 5 × 10 4 cells per well. After incubation for 24 hours, the cells were incubated with K2® Transfection Reagent (Biontex) for XRE promoter Transiently overexpressed. Thereafter, the cells were treated with fine dust (DPM) at a concentration of 100 μg / ml to confirm whether the XRE promoter was overactivated by DPM.
사삼 추출물을 20㎍/㎖, 200㎍/㎖의 농도로 DPM과 함께 섞어 세포에 처리한 후 24시간 동안 37℃, 5% CO2 배양기에서 배양하였다. 배양 후 배지를 제거하고 각 well당 100ul의 passive lysis buffer를 첨가하여 세포를 깨어준 후 15000rpm으로 원심분리 하여 상등액만 취하였다. Dual-Luciferase® Reporter 1000 Assay Systems 키트(Promega)를 이용하여 XRE promoter의 활성도를 측정하였다. 처리하지 않은 well의 형광정도를 기준으로 하여 사삼 추출물이 DPM에 의해 과활성화된 XRE의 활성에 미치는 영향을 평가하였으며 그 결과를 도 1에 나타내었다. 모든 결과값은 3회 이상의 독립적인 실험을 거쳐 평균±표준편차(SD)로 나타내었다.The ginseng extract was mixed with DPM at a concentration of 20 μg / ml and 200 μg / ml, and the cells were cultured in a 5% CO 2 incubator at 37 ° C. for 24 hours. After the culture, the medium was removed and 100 ul of passive lysis buffer was added to each well to wake the cells. The supernatant was centrifuged at 15000 rpm. The activity of the XRE promoter was measured using the Dual-Luciferase® Reporter 1000 Assay Systems Kit (Promega). Based on the degree of fluorescence of the untreated wells, the effect of the extract of Xanthium ginseng on hyperactivated XRE activity by DPM was evaluated. The results are shown in FIG. All results were expressed as mean ± standard deviation (SD) after three or more independent experiments.
그 결과, 도 1에 나타난 바와 같이, DPM에 의해 XRE 과활성 됨을 확인 하였고, 이후, 사삼 추출물 처리시 DPM에 의한 XRE의 과활성을 정상수준으로 회복해 주는 것을 확인하였다. As a result, as shown in FIG. 1, it was confirmed that XRE was activated by DPM, and then it was confirmed that DPE-induced hyperactivity of XRE was recovered to a normal level in the treatment of extract of ginseng sap.
이를 통해, 사삼 추출물이 DPM에 의한 XRE의 과활성을 조절하여 피부자극을 방어해 줄 수 있음을 알 수 있다.This suggests that the extract of Xanthomonas oryzae can protect skin irritation by regulating the hyperactivity of XRE by DPM.
제조예Manufacturing example 1. 화장품의 제조 1. Manufacture of cosmetics
1. 유연화장수(스킨로션)의 제조1. Manufacture of softening longevity (skin lotion)
사삼 추출물의 화합물을 유효성분으로 포함하는 유연화장수를 하기 조성과 같이 통상의 방법에 따라 제조하였다.The softened longevity water containing a compound of the extract of Xanthan gum extract as an active ingredient was prepared by a conventional method such as the following composition.
유연화장수의 조성:Composition of softening longevity:
사삼 추출물의 화합물 0.1 중량％, 베타-1,3-글루칸 1.0 중량％, 부틸렌글리콜 2.0 중량％, 프로필렌글리콜 2.0 중량％, 카르복시비닐폴리머 0.1 중량％, 피이지-12 노닐페닐에테르 0.2 중량％, 폴리솔베이트80 0.4 중량％, 에탄올 10.0 중량％, 트리에탄올아민 0.1 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.1% by weight of a compound of ginseng extract, 1.0% by weight of beta-1,3-glucan, 2.0% by weight of butylene glycol, 2.0% by weight of propylene glycol, 0.1% by weight of carboxyvinyl polymer, 0.2% 0.05% by weight of coloring matter, 0.05% by weight of fragrance, 100% by weight of purified water, and 0.05% by weight of a preservative, 0.4% by weight of polysorbate 80, 10.0% by weight of ethanol,
2. 영양화장수(2. Nourishing lotion ( 밀크로션Milk lotion )의 제조)
사삼 추출물의 화합물을 유효성분으로 포함하는 영양화장수를 하기 조성과 같이 통상의 방법에 따라 제조하였다.A nutritional lotion comprising a compound of extract of Aspergillus oryzae as an active ingredient was prepared according to a conventional method such as the following composition.
영양화장수의 조성:Composition of nutrition lotion:
사삼 추출물의 화합물 0.1 중량％, 베타-1,3-글루칸 1.0 중량％, 밀납 4.0 중량％, 폴리솔베이트60 1.5 중량％, 솔비탄세스퀴올레이트 1.5 중량％, 유동파라핀 0.5 중량％, 카프릴릭/카프릭트리글리세라이드 5.0 중량％, 글리세린 3.0 중량％, 부틸렌글리콜 3.0 중량％, 프로필렌글리콜 3.0 중량％, 카르복시비닐폴리머 0.1 중량%, 트리에탄올아민 0.2 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.1% by weight of a compound of the extract of Xanthan gum extract, 1.0% by weight of beta- 1,3-glucan, 4.0% by weight of beeswax, 1.5% by weight of polysorbate 60, 1.5% by weight of sorbitan sesquioleate, 0.5% by weight of liquid paraffin, / Carboxy triglyceride 5.0 wt%, glycerin 3.0 wt%, butylene glycol 3.0 wt%, propylene glycol 3.0 wt%, carboxyvinyl polymer 0.1 wt%, triethanolamine 0.2 wt%, preservative 0.05 wt%, coloring matter 0.05 wt% 0.05% by weight of fragrance, 100% by weight of purified water,
3. 영양크림의 제조3. Manufacture of nutritional cream
사삼 추출물의 화합물을 유효성분으로 포함하는 영양크림을 하기 조성과 같이 통상의 방법에 따라 제조하였다.A nutritional cream containing the extract of Aspergillus oryzae as an active ingredient was prepared according to a conventional method such as the following composition.
영양크림의 조성:Composition of nutrition cream:
사삼 추출물의 화합물 0.2 중량％, 베타-1,3-글루칸 5.0 중량％, 밀납 10.0 중량％, 폴리솔베이트60 1.5 중량％, 피이지 60 경화피마자유 2.0 중량％, 솔비탄세스퀴올레이트 0.5 중량％, 유동파라핀 10.0 중량％, 스쿠알란 5.0 중량％, 카프릴릭/카프릭트리글리세라이드 5.0 중량％, 글리세린 5.0 중량％, 부틸렌글리콜 3.0 중량％, 프로필렌글리콜 3.0 중량％, 트리에탄올아민 0.2 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.2% by weight of a compound of the crude extract, 5.0% by weight of beta- 1,3-glucan, 10.0% by weight of wax, 1.5% by weight of polysorbate 60, 2.0% by weight of hydrogenated castor oil, 0.5% by weight of sorbitan sesquioleate, , Paraffin 10.0% by weight, squalane 5.0% by weight, caprylic / capric triglyceride 5.0% by weight, glycerin 5.0% by weight, butylene glycol 3.0% by weight, propylene glycol 3.0% by weight, triethanolamine 0.2% by weight, preservative 0.05 0.05% by weight of pigment, 0.05% by weight of fragrance, 100% by weight of purified water,
4. 마사지크림의 제조4. Manufacture of massage cream
사삼 추출물의 화합물을 유효성분으로 포함하는 마사지크림을 하기 조성과 같이 통상의 방법에 따라 제조하였다.A massaging cream containing a compound of ginseng extract as an active ingredient was prepared by a conventional method such as the following composition.
마사지 크림의 조성: Composition of massage cream:
사삼 추출물의 화합물 0.1 중량％, 베타-1,3-글루칸 3.0 중량％, 밀납 10.0 중량％, 폴리솔베이트60 1.5 중량％, 피이지 60 경화피마자유 2.0 중량％. 솔비탄세스퀴올레이트 0.8 중량％, 유동파라핀 40.0 중량％, 스쿠알란 5.0 중량％, 카프릴릭/카프릭트리글리세라이드 4.0 중량％, 글리세린 5.0 중량％, 부틸렌글리콜 3.0 중량％, 프로필렌글리콜 3.0 중량％, 트리에탄올아민 0.2 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.1% by weight of a compound of the extract of Xanthan gum, 3.0% by weight of beta-1,3-glucan, 10.0% by weight of wax, 1.5% by weight of polysorbate 60, 2.0% by weight of hardened castor oil. By weight of glycerin, 3.0% by weight of butylene glycol, 3.0% by weight of propylene glycol, 4.0% by weight of carrageenan / capric triglyceride, 0.8% by weight of sorbitan sesquioleate, 40.0% by weight of liquid paraffin, 0.2% by weight of triethanolamine, 0.05% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of fragrance, 100%
5. 팩의 제조5. Manufacture of pack
사삼 추출물의 화합물을 유효성분으로 포함하는 팩을 하기 조성과 같이 통상의 방법에 따라 제조하였다.A pack containing a compound of extract of Aspergillus oryzae as an active ingredient was prepared according to a conventional method such as the following composition.
팩의 조성:Composition of pack:
사삼 추출물의 화합물 0.2 중량％, 베타-1,3-글루칸 1.0 중량％, 폴리비닐알콜 13.0 중량％, 소듐카르복시메틸셀룰로오스 0.2 중량％, 글리세린 5.0 중량％, 알란토인 0.1 중량％, 에탄올 6.0 중량％, 피이지-12 노닐페닐에테르 0.3 중량％, 폴리솔베이트 60 0.3 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.1% by weight of allantoin, 6.0% by weight of ethanol, 0.2% by weight of the extract of the present invention, 0.2% by weight of the compound of the extract of Xanthium ginseng, 1.0% by weight of beta-1,3-glucan, 13.0% by weight of polyvinyl alcohol, 0.2% by weight of sodium carboxymethyl cellulose, 0.3% by weight of iso-12 nonylphenyl ether, 0.3% by weight of polysorbate 60, 0.05% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of fragrance,
제조예Manufacturing example 2. 2. 피부외용제의Topical 제조 Produce
1. 젤의 제조1. Manufacture of gel
사삼 추출물을 유효성분으로 포함하는 젤을 하기 조성과 같이 통상의 방법에 따라 제조하였다.A gel containing the extract of Xanthium ginseng as an active ingredient was prepared by a conventional method such as the following composition.
젤의 조성:Composition of gel:
사삼 추출물의 화합물 0.1 중량％, 베타-1,3-글루칸 0.1 중량％, 에틸렌디아민초산나트륨 0.05 중량％, 글리세린 5.0 중량％, 카르복시비닐폴리머 0.3 중량％, 에탄올 5.0 중량％, 피이지-60 경화피마자유 0.5 중량％, 트리에탄올아민 0.3 중량％, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량％0.1% by weight of a compound of the extract of Xanthan gum extract, 0.1% by weight of beta-1,3-glucan, 0.05% by weight of sodium ethylenediamineacetate, 5.0% by weight of glycerin, 0.3% by weight of carboxyvinyl polymer, 5.0% by weight of ethanol, 0.05 weight% of free, 0.3 weight% of triethanolamine, 0.05 weight% of preservative, 0.05 weight% of pigment, 0.05 weight% of perfume, 100 weight% of purified water,
2. 연고의 제조2. Manufacture of ointment
사삼 추출물의 화합물을 유효성분으로 포함하는 연고를 하기 조성과 같이 통상의 방법에 따라 제조하였다.Ointment containing a compound of extract of Xanthan gum extract as an active ingredient was prepared by a conventional method such as the following composition.
연고의 조성:Composition of ointment:
사삼 추출물의 화합물 0.5 중량％, 베타-1,3-글루칸 10.0 중량%, 밀납 10.0 중량%, 폴리솔베이트60 5.0 중량%, 피이지 60 경화피마자유 2.0 중량%, 솔비탄세스퀴올레이트 0.5 중량%, 바셀린 5.0 중량%, 유동파라핀 10.0 중량%, 스쿠알란 5.0 중량%, 쉐어버터 3.0 중량%, 카프릴릭/카프릭트리글리세라이드 5.0 중량%, 글리세린 10.0 중량%, 프로필렌글리콜 10.2 중량%, 트리에탄올아민 0.2 중량%, 방부제 0.05 중량％, 색소 0.05 중량％, 향료 0.05 중량％, 정제수 to 100 중량%0.5% by weight of a compound of the extract of Xanthan gum extract, 10.0% by weight of beta- 1,3-glucan, 10.0% by weight of wax, 5.0% by weight of polysorbate 60, 2.0% by weight of hydrogenated castor oil, 0.5% by weight of sorbitan sesquioleate, , 5.0% by weight of vaseline, 10.0% by weight of liquid paraffin, 5.0% by weight of squalane, 3.0% by weight of shea butter, 5.0% by weight of caprylic / capric triglyceride, 10.0% by weight of glycerin, 10.2% by weight of propylene glycol, 0.05% by weight of preservative, 0.05% by weight of pigment, 0.05% by weight of fragrance, 100% by weight of purified water,
3. 국소투여용 3. For topical administration 약제(겔 연고제) 의Of the drug (gel ointment) 제조 Produce
사삼 추출물의 화합물을 유효성분으로 포함하는 겔 연고제를 하기 조성과 같이 통상의 방법에 따라 제조하였다.A gel ointment agent containing a compound of extract of Xanthan gum extract as an active ingredient was prepared according to a conventional method such as the following composition.
겔 연고제의 조성:Composition of gel ointment agent:
사삼 추출물의 화합물 0.5 중량％, 베타-1,3-글루칸 10.0 중량%, 폴리아크릴산(Carbopol 940) 1.5 중량%, 이소프로판올 5.0 중량%, 헥실렌글리콜 25.0 중량%, 트리에탄올아민 1.7 중량%, 탈이온수 to 100 중량%0.5% by weight of a compound of the extract of Bombyx mori extract, 10.0% by weight of beta-1,3-glucan, 1.5% by weight of polyacrylic acid (Carbopol 940), 5.0% by weight of isopropanol, 25.0% by weight of hexylene glycol, 1.7% by weight of triethanolamine, 100 wt%
4. 국소 투여용 약제(4. Drugs for topical administration ( 패취제Patch )의 제조)
사삼 추출물의 화합물을 유효성분으로 포함하는 패취제를 하기 조성과 같이 통상의 방법에 따라 제조하였다.A patch containing a compound of extract of Aspergillus oryzae as an active ingredient was prepared according to a conventional method such as the following composition.
패취제의 조성:Composition of the patch:
사삼 추출물의 화합물 0.5 중량%, 베타-1,3-글루칸 3.0 중량%, 헥실렌글리콜 20.0 중량%, 디에틸아민 0.7 중량%, 폴리아크릴산(Carbopol 934P) 1.0 중량%, 아황산나트륨 0.1 중량%, 폴리옥시에틸렌라우릴에테르(E.O=9) 1.0 중량%, 폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) 1.0 중량%, 점성의 파라핀 오일 2.5 중량%, 카프릴산에스테르/카프르산에스테르(Cetiol LC) 2.5 중량%, 폴리에틸렌글리콜400 3.0 중량%, 탈이온수 to 100 중량%(Carbopol 934P), 0.1% by weight of sodium sulfite, 0.1% by weight of polyvinylpyrrolidone, 0.5% by weight of a compound of the extract of Xanthan gum extract, 3.0% by weight of beta-1,3-glucan, 20.0% by weight of hexylene glycol, 1.0% by weight of oxyethylene lauryl ether (EO = 9), 1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000), 2.5% by weight of viscous paraffin oil, caprylic acid ester / ) 2.5% by weight, polyethylene glycol 400 3.0% by weight, deionized water to 100%
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (5)
A composition for external application for skin for protecting against skin damage caused by fine dusts containing extract of ginseng as an active ingredient.
상기 조성물은 미세먼지에 의해 과발현된 XRE(Xenobiotic Response Element)의 활성을 감소시키는 것을 특징으로 하는 피부외용제 조성물.
The method according to claim 1,
Wherein the composition reduces the activity of a Xenobiotic Response Element (XRE) overexpressed by fine dust particles.
상기 추출물은 물, 탄소수 1 내지 4의 저급 알콜 또는 이들의 혼합용매로 추출한 것인, 피부외용제 조성물.
The method according to claim 1,
Wherein the extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
A cosmetic composition for preventing skin damage caused by fine dusts containing extracts of ginseng as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170002437A KR20180081327A (en) | 2017-01-06 | 2017-01-06 | Composition for skin conditioning comprising Adenophora Stricta extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170002437A KR20180081327A (en) | 2017-01-06 | 2017-01-06 | Composition for skin conditioning comprising Adenophora Stricta extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180081327A true KR20180081327A (en) | 2018-07-16 |
Family
ID=63048206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170002437A KR20180081327A (en) | 2017-01-06 | 2017-01-06 | Composition for skin conditioning comprising Adenophora Stricta extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180081327A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102201904B1 (en) * | 2019-08-27 | 2021-01-12 | 주식회사 코씨드바이오팜 | Method for extracting vanillic acid with high yield from adenophora stricta root |
| KR20210033627A (en) | 2019-09-19 | 2021-03-29 | 성균관대학교산학협력단 | Composition for preventing, treating, or improving skin disease induced by air pollutants comprising resorcinol or phenylethyl resorcinol |
| KR20230071413A (en) * | 2021-11-16 | 2023-05-23 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
-
2017
- 2017-01-06 KR KR1020170002437A patent/KR20180081327A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102201904B1 (en) * | 2019-08-27 | 2021-01-12 | 주식회사 코씨드바이오팜 | Method for extracting vanillic acid with high yield from adenophora stricta root |
| KR20210033627A (en) | 2019-09-19 | 2021-03-29 | 성균관대학교산학협력단 | Composition for preventing, treating, or improving skin disease induced by air pollutants comprising resorcinol or phenylethyl resorcinol |
| KR20230071413A (en) * | 2021-11-16 | 2023-05-23 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102171133B1 (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
| KR20150100288A (en) | Cosmetic composition comprising the extract of crude drug fermentation using the black yeast | |
| KR102144568B1 (en) | Composition for skin conditioning comprising Morus alba L. extract | |
| JP5626650B2 (en) | Cosmetic composition containing orchid extract | |
| KR20180081327A (en) | Composition for skin conditioning comprising Adenophora Stricta extract | |
| KR101917645B1 (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
| KR101525691B1 (en) | Cosmetic composition containing leonurus sibiricus extract for improving skin allergy | |
| JP2009242311A (en) | Scf secretion inhibitor and skin care preparation for external use for making skin pore inconspicuous | |
| KR101587077B1 (en) | Composition containing fermentated opuntia humifusa showing biological activity of skin | |
| KR20230135528A (en) | Cosmetic compositions comprising astaxanthin, epidermal growth factor and mixed extracts of natural product as effective components | |
| KR101974502B1 (en) | Cosmetic composition for anti-allergy and for improving atopic dermatitis comprising extract of anemone reflexa stephan as active ingredient | |
| KR102123645B1 (en) | Cosmetic composition with Angelica japonica extract | |
| KR101558186B1 (en) | Cosmetic composition containing Phyllanthus urinaria extrancts | |
| KR102476671B1 (en) | Composition for skin conditioning comprising Scutellaria baicalensis Georgi extract | |
| KR101852252B1 (en) | Method for culturing Lilium Candidum Cell and Functional skin external application comprising Lilium Candidum Cell Culture Extract | |
| KR20020061196A (en) | Cosmetic compositions containing scutellaria extracts | |
| KR20150106111A (en) | Composition for preventing or treating ultravilet-induced skin damage | |
| KR102416652B1 (en) | Cosmetic composition for anti-irritation due to the particulate matter and improving skin conditions | |
| KR102675065B1 (en) | Cosmetic composition from Connarus semidecandrus extracts for improving atopic dermatitis | |
| KR102555418B1 (en) | Cosmetic composition for protecting skin comprising mixed extracts of androgrphis paniculta and selaginella tamaricina fermanated by bacillus subtillus j2k-351 strain | |
| KR101719723B1 (en) | Cosmetic composition comprising the extract of Ensete lasiocarpum as active ingredient | |
| KR102481125B1 (en) | A composition for skin anti-pollution containing a daughter-in-law navel extract | |
| KR101549148B1 (en) | Composition for protecting and curing human keratinocyte against UV-B comprising Phryma leptostachya var. asiatica Hara ethanol extract | |
| US10835470B2 (en) | Cosmetics composition containing ginsenoside as active ingredient | |
| KR20160082113A (en) | Skin external composition for anti-anging comprising compound K and panaxydol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal |